Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people ...
MedPage Today on MSN
New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden
Bispecific antibody fares well against faricimab, two gene therapies extend treatment inte ...
Vonaprument reduced the proportion of eyes with clinically meaningful vision loss, though not uniformly across doses. Through ...
K8 slowed disease progression and trended towards improving visual acuity, which Inflammasome says warrants the drug’s further evaluation.
Bausch + Lomb announced topline results from its phase 2 study of BL1107 in patients with glaucoma. According to the company, ...
It’s a fine measure of the curator Joel Smith’s visual and emotional acuity that the first standout images one encounters on ...
After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerat ...
Dompé advances cenegermin-bkbj into Phase 3 for NAION, a rapid vision-loss condition with no FDA-approved treatment options.
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 months The most common adverse events ...
Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data from its clinical studies of ...
Grants of between EUR 65,000 and EUR 250,000 have been awarded to projects that cover intellectual, physical and vision ...
Mice have notoriously blurry vision, and scientists long assumed they relied on smell and whiskers to navigate their world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results